Novasep and instrAction expand alliance to include taxane purification

Companies will develop solutions to change manufacturing paradigm for new and generic anti-cancer compounds

15-Feb-2011 - Novasep, a leading supplier of manufacturing solutions to the life science industries, and instrAction, a manufacturer of innovative chromatographic stationary phases for API purification processes, announced they have expanded their worldwide strategic alliance to include the purification of ...

Siegfried reports distinct sales increase for first 3 quarters of 2010

29-Oct-2010 - The Siegfried Group reports sales of CHF 218.5 million for the first 9 months of the 2010 financial year, representing an increase of 8.8% in Swiss francs and of 12.1% in local currencies over the comparable period the previous year. Siegfried sold active pharmaceutical ingredients and ...

Aterovax Signs Agreement with SPI-BIO to Distribute its sPLA2 Activity Test in Europe for Research Use

21-Apr-2010 - Aterovax SA announced the signing of a 3 year, exclusive agreement with SPI-Bio, a specialist distributor of products and services in drug development, to distribute and sell Aterovax’s sPLA2 activity test in Europe to academic and research laboratories for research use. Financial terms were not ...

The Dishman Group announces strategic alliance with Codexis

19-Feb-2010 - The Dishman Group announced the formation of a strategic alliance with Codexis, Inc. a California based biotechnology company. This strategic partnership covers the use of Codexis’ proprietary enzymatic biocatalysis technology for the manufacture of building blocks, intermediates and APIs for ...

Evonik strengthens its exclusive synthesis business in US

Evonik acquires Eli Lilly and Company’s U.S. Tippecanoe manufacturing site

21-Oct-2009 - Evonik Industries AG has agreed to acquire Indianapolis, Indiana-based Eli Lilly and Company’s Tippecanoe Laboratories manufacturing facility in Lafayette, Indiana. The site, which employs about 700, manufactures active pharmaceutical ingredients (API) and precursor materials for the ...

Cambridge Major To Partner with Novacta Biosystems

06-Apr-2009 - Cambridge Major Laboratories and Novacta Biosystems have announced a collaboration combining respective expertise in process development, custom synthesis and biocatalysis. Novacta will develop biocatalytic approaches to target chiral intermediates which CML will then scale-up in facilities in ...

Codexis to Establish New R&D Facility in Singapore to Support Expanding Generics Business

28-Aug-2006 - Codexis announced that it will establish a research and development center in Singapore, scheduled to open in the third quarter of 2007. The R&D center will focus on new product development for the company's API and generics business. When fully staffed, the center is expected to house up to 80 ...

Clariant's Pharmaceutical Fine Chemicals is now 'Archimica'

Separation from Clariant Complete, Headquarter in Germany

06-Jul-2006 - The organization formerly known as the Pharmaceutical Fine Chemicals business of Clariant is now Archimica -- the world's leading global fine chemicals business focused solely on commercialization solutions for the pharmaceutical industry. The new business is comprised of virtually all assets ...

India and China Presents Opportunities for European Pharmaceutical and Biotechnology Companies to Capitalise on

09-Mar-2005 - Despite having over a third of the world's population, Asia accounts for only one fifth of global pharmaceutical drug consumption. As income levels rise, demand from this large population base is set to burgeon, opening up new growth opportunities for pharmaceutical and biotechnology companies. ...

API Companies Look for Solutions to Problems of Overcapacity

Lack of Capability Differentiation and Competition from Low-cost Manufacturers

30-Nov-2004 - Manufacturers in the crowded and highly fragmented European active pharmaceutical ingredients (API) market are struggling to overcome a variety of challenges. One of the most pressing of these is the problem of overcapacity. Additionally, constant price erosions and the large number of ...